Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.19 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Joinn Laboratories (China) Co's Beneish M-Score or its related term are showing as below:
SHSE:603127'
s Beneish M-Score Range Over the Past 10 Years
Min: -2.87 Med: -2.19 Max: 0.47
Current: -2.19
During the past 13 years, the highest Beneish M-Score of Joinn Laboratories (China) Co was 0.47. The lowest was -2.87. And the median was -2.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co Beneish M-Score Chart
SHSE:603127 vs TMO, DHR, IDXX: Beneish M-Score Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co Beneish M-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Beneish M-Score falls into.
Joinn Laboratories (China) Co Beneish M-Score Calculation
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Joinn Laboratories (China) Co for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.2074
+
0.528 * 1.4351
+
0.404 * 1.1283
+
0.892 * 0.8514
+
0.115 * 1
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.1402
+
4.679 * -0.001191
-
0.327 * 1.0694
=
-2.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(0 / (0 + 1116.23))
/
(0 / (0 + 1070.828))
=
0
/
0
=
1
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(495.079 - 0
-
507.029)
/
10036.866
=
-0.001191
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Joinn Laboratories (China) Co has a M-score of -2.19 suggests that the company is unlikely to be a manipulator.
Joinn Laboratories (China) Co (SHSE:603127) has a Beneish M-Score of -2.19 as of Aug. 01, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Joinn Laboratories (China) Co and its competitors. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #146 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 75.6%.
Is Joinn Laboratories (China) Co's Beneish M-Score too high?
Joinn Laboratories (China) Co's current Beneish M-Score is -2.19. Based on the distribution chart, Joinn Laboratories (China) Co ranks #146 out of 193 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #146 out of 193 companies for Beneish M-Score. This places Joinn Laboratories (China) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Joinn Laboratories (China) Co and its competitors. Joinn Laboratories (China) Co's current Beneish M-Score is -2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current Beneish M-Score is -2.19. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Beneish M-Score is -2.19 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
Beneish M-Score: -2.19
GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
